Sanchez Katherine, Page David B, Urba Walter
Earle A. Chiles Research Institute, 4805 Northeast Glisan Street, North Pavilion, 2N, Portland, OR 97213, USA.
Earle A. Chiles Research Institute, 4805 Northeast Glisan Street, North Pavilion, 2N, Portland, OR 97213, USA.
Surg Oncol Clin N Am. 2019 Jul;28(3):387-401. doi: 10.1016/j.soc.2019.02.009. Epub 2019 Apr 5.
Immune checkpoint inhibitors (ICIs) are therapeutic antibodies that target regulatory molecules on T cells and represent the most widely used FDA-approved class of immunotherapy. ICIs are associated with unique immune-mediated toxicities called immune-related adverse events. These toxicities may affect any organ system, and their precise mechanisms of action remain under investigation. Current evidence suggests that activation of T cells is involved, although other components of the immune response have been implicated. This article summarizes toxicities, potential mechanisms of action, management strategies, and other clinical considerations. Unique mechanisms of action and immune-related toxicities of other FDA-approved classes of immunotherapy are reviewed.
免疫检查点抑制剂（ICIs）是一类靶向T细胞上调节分子的治疗性抗体，是美国食品药品监督管理局（FDA）批准的应用最为广泛的免疫疗法。ICIs与称为免疫相关不良事件的独特免疫介导毒性有关。这些毒性可能影响任何器官系统，其确切作用机制仍在研究中。目前的证据表明，虽然免疫反应的其他成分也有涉及，但T细胞的激活与之有关。本文总结了毒性、潜在作用机制、管理策略及其他临床注意事项。还对FDA批准的其他免疫疗法的独特作用机制和免疫相关毒性进行了综述。
